The Economic Burden of CLL in Canada Associated with the Adoption of Oral Targeted Therapy.

Lachaine J¹, Beauchemin C¹, Guinan K¹, Thebault P², AW A³*, Banerji V⁴*, Fleury I⁵*, Owen C⁶*

¹University of Montreal, Montreal, QC, Canada, ²PeriPharm, Montreal, QC, Canada, ³Ottawa Hospital, Ottawa, ON, Canada, ⁴CancerCare Manitoba, Winnipeg, MB, Canada, ⁵Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, ⁶Foothills Medical Centre, Calgary, AB, Canada, *These 4 authors had an equal contribution to this project

Presented at CAPT 2019 Annual Conference, October 21-22, 2019, MaRS Discovery Districts meeting and event space, Toronto, Ontario, Canada
Disclaimer

• Jean Lachaine and Catherine Beauchemin are partners at PeriPharm, a company that has served as a consultant to AbbVie and has received funding from AbbVie.

• Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, and Philippe Thebault, from PeriPharm, have participated in the study conduct, data interpretation and the approval of the abstract.

• Dr. Andrew Aw has received honoraria into a separate account within the Ottawa Hospital Research Institute, for research/academic use only. Dr. Versha Banerji has received research funding from CIHR, CancerCare Manitoba, Research Manitoba, Janssen and Abbvie and has served as a consultant to Abbvie, Janssen AstraZeneca, Gilead, Roche, and Lundbeck. Dr. Isabelle Fleury has provided advisory consultations for Abbvie, AstraZeneca, BMS, Gilead, Janssen, Merck, Novartis, Roche and Seattle Genetics and has given presentations for Abbvie, Janssen, Novartis, Roche. Dr. Carolyn Owen has received honoraria from Abbvie, Janssen, Roche, Gilead, Merck, AstraZeneca, and Teva.

• The authors would like to thank Jean-Nicolas Charron for his support in the model development and Erin Hillhouse for the writing of the abstract. Erin Hillhouse and Jean Nicolas Charron are employees of PeriPharm and have received funding from PeriPharm for providing medical writing and supporting the economic modelling respectively. No author has received funding for developing the abstract. AbbVie participated in the design and provided financial support for the study. AbbVie reviewed and approved this publication.
Introduction

• For a number of CLL patients, watchful waiting may be an appropriate treatment approach.

• Until recently, chemoimmunotherapy (CIT) regimens were the standard first-line treatments for patients with CLL.

• In 2015, Health Canada approved two oral targeted therapies (OTT):
  o Ibrutinib for relapsed/refractory CLL patients with del (17p)
  o Idelalisib in combination with rituximab for patients with relapse/refractory CLL.

• The higher cost of OTT in comparison to CIT treatments suggests a significant impact on the budget of public and private payers, and on patient co-payments

Objective

• The objective of this study was to predict the future direct costs, as well as the number of CLL treated patients in the era of OTT in Canada.
Methods

• The economic burden of OTT compared to CIT for treating patients with CLL was assessed from 2011 to 2025.

• **Intervention & comparator**
  o **CIT Scenario:** CIT remained the standard of care over time
  o **OTT Scenario:** CIT was considered the standard of care before 2015, while OTT was considered for fludarabine ineligible CLL patients and those with a 17-p deletion starting in 2015.

• **Population:**
  o Patients were stratified according to age, phase of CLL treatment ((WW), first-line or relapse), fitness level as well as mutation status.
  o The study population in 2011 was defined based on incident cases from 2000 to 2010.
Methods

- **Model Structure**: A Markov model was developed including four health states: watchful waiting, first-line treatment, relapse and death.
Methods

- **Costs:** costs of therapy, follow-up/monitoring and adverse event management were included.

- **Perspective:** public healthcare perspective

- **Time Horizon:** 15 years (2011-2025)

- **Clinical Effectiveness:**
  - Health-state transition probabilities were estimated based on PFS and OS from pivotal clinical trials and Canadian all-cause mortality rates.
  - The trials were selected based on the best evidence available for the most widely used treatment regimens in clinical practice, referring to product monographs, clinical guidelines as well as key opinion leaders.
Patients living with CLL will increase over time

- The number of patients living with CLL will increase with time and will increase further with improved treatment options especially the ability to treat chemo ineligible and 17p deletion patients.
- OTT scenario: CLL patients treated projected to increase from 8,301 in 2011 to 14,654 by 2025 (77% increase).
- CIT scenario: the number of CLL patients treated would increase from 8,248 to 12,521 (52% increase), by 2025.

*Excluding watchful waiting patients
• **OTT scenario:** total annual costs of CLL management will increase from Can$60.8 million to Can$957.5 million from 2011 to 2025, respectively (15.7-fold increase).

• **CIT scenario:** would also increase, but less drastically, reaching Can$107.6 million (1.76-fold increase) in 2025. When comparing both scenarios, OTT would result in additional expenditures of Can$3.6 billion, from 2014 to 2025.
Conclusions

• The projected significant cost increase from 2011 to 2025 are explained by:
  o Increased number of CLL patients eligible for therapy
  o Increased survival of CLL patients due to more effective therapy
  o Increased treatment costs per patients

• Changes in clinical strategies, such as implementation of a fixed OTT treatment duration, would help alleviate financial burden.
Impact of patient-targeted financial incentives on healthcare costs: A systematic review of randomized controlled trials

Brittany Humphries
Department of Health Research Methods, Evidence and Impact
McMaster University
Disclosure

PhD candidate, Health Research Methodology, McMaster University

Associate, HTA and Health Economics, PDCI Market Access

President, McMaster Student Chapter, International Society for Pharmacoeconomics and Outcomes Research

No funding was received for this study.
Background

• In this era of rising healthcare costs, there is a growing interest in understanding how health insurance policies can be used to support effective, efficient, affordable and accessible care.

• The costs borne by individuals may affect what services they will seek out or use.
Background

• In this era of rising healthcare costs, there is a growing interest in understanding how health insurance policies can be used to support effective, efficient, affordable and accessible care.

• The costs borne by individuals may affect what services they will seek out or use.

We do not have a comprehensive understanding of the research that has been conducted on patient-targeted financial incentives in a randomized experimental environment.
Objective

• To describe the evidence landscape on the use of patient-targeted financial incentives in randomized controlled trials (RCTs).
Objective

• To describe the evidence landscape on the use of patient-targeted financial incentives in randomized controlled trials (RCTs).

Today I will present preliminary findings regarding the impact of patient-targeted financial incentives on healthcare costs.
Methods

• Systematic review conducted according to PRISMA guidelines.

• Searched electronic databases, clinical trial registries, and websites of health economic organisations to identify RCTs in which a patient-targeted financial incentive was provided within a healthcare system.

• Two reviewers independently reviewed titles, abstracts and full texts to assess study eligibility.

• Data was abstracted using a piloted form.
**Methods**

**Data extraction form**

<table>
<thead>
<tr>
<th><strong>Trial characteristics</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• First author</td>
</tr>
<tr>
<td>• Year</td>
</tr>
<tr>
<td>• Country</td>
</tr>
<tr>
<td>• Jurisdiction</td>
</tr>
<tr>
<td>• Context (rural, urban, mixed)</td>
</tr>
<tr>
<td>• Population of interest</td>
</tr>
<tr>
<td>• Randomization procedure</td>
</tr>
<tr>
<td>• Unit of randomization</td>
</tr>
<tr>
<td>• Type and magnitude of intervention</td>
</tr>
<tr>
<td>• Type and magnitude of comparator</td>
</tr>
<tr>
<td>• Time horizon</td>
</tr>
<tr>
<td>• Sponsor</td>
</tr>
</tbody>
</table>
Methods

Data extraction form

**Trial characteristics**
- First author
- Year
- Country
- Jurisdiction
- Context (rural, urban, mixed)
- Population of interest
- Randomization procedure
- Unit of randomization
- Type and magnitude of intervention
- Type and magnitude of comparator
- Time horizon
- Sponsor

**Outcome characteristics**
- Outcome
- Definition
- Analysis approach
- Time point of analysis
- Measure of outcome
- Result
- P-value
- 95% confidence interval
Results

- 15,845 records identified
- 152 records included in the full text review
- 76 records had data extracted (1,600+ outcomes)
Results

15,845 records identified

152 records included in the full text review

76 records had data extracted (1,600+ outcomes)

25 records with outcome data that was categorized as a healthcare cost
Results
Costs to Payers

• 17 records that measured costs from the perspective of healthcare payers.

  • 10 (58.8%) found no difference and 4 (23.5%) an increase in total healthcare costs.

  • 9 articles (52.9%) found an increase in costs associated with the intervention when evaluating specific cost components.
Results

Costs to Patients

• 10 records that measured the costs to patients.

  • 6 (60.0%) found a significant decrease and 4 (40.0%) no difference in out-of-pocket costs.
Thank you

Michael Zoratti
Andrew Irwin
Zhou Ting
Nora Chen
Feng Xie
Questions?

humphrib@mcmaster.ca
EARLY HIV TREATMENT AS PREVENTION (TasP) AMONG FEMALE SEX WORKERS IN COTONOU, BENIN, WEST AFRICA

Mamadou Diallo, Ph.D. Msc Épidémiologie
Postdoctoral Fellow
Research Laboratory in Chronic Pain Epidemiology
Université du Québec en Abitibi-Témiscamingue
Introduction

- **Western and central Africa**
  - The second most affected region by the HIV epidemic
  - 5 million people living with HIV (PLHIV) in 2018
  - HIV testing and antiretroviral therapy (ART) coverage are among the lowest worldwide

- **UNAIDS 2020 targets** remain low
  - 42% of PLHIV knowing their status
  - 35% of those who know their status are on ART
  - Only 25% of those on ART suppress their viral load

- **FSWs contributed to between**
  - 32–84% of HIV prevalent cases among men
  - 18% in the general population of women

- **Female sex workers (FSWs)** and their clients play a central role in the HIV transmission dynamics

- No special programs to facilitate FSWs to access and retain in ART

- FSWs ideal target for TasP/PrEP

---

UNAIDS 2018

King et al., J Infect Dis. 2017; Kane et al. Int J STD AIDS. 2009; Alary et al., AIDS 2004
Objectives

In line with UNAIDS recommendations extending ART to all HIV-infected individuals, we conducted this demonstration project on immediate treatment as prevention (TasP) among FSWs in Cotonou, Benin, West Africa.

Specific Objective included assessing:

✓ The retention rate
✓ The adherence to treatment
✓ Restoration of CD4 count
✓ Viral response to treatment
✓ Development of drug resistance
Methods

Study Design
- This was a cohort study (Participants followed up between 12 and 24 months)

Study Population
- Female sex workers (FSWs)
- Greater Cotonou area and suburbs

Eligibility criteria
- Professional FSWs (whose income come from sex work)
- Aged 18 and over
- Confirmed HIV-positive
- ART-naive
Results (1)

Cascade of follow up

- 7 (6.5%) participants withdrew
- 15 (14.0%), went back to their country of origin
- 19 (17.8%), traveled to others cities
- One died
- One got married and left sex work

- Retention rate of 59.8%

### Population Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of origin</td>
<td>107</td>
<td>100%</td>
</tr>
<tr>
<td>Benin</td>
<td>56</td>
<td>52.3%</td>
</tr>
<tr>
<td>Other countries</td>
<td>51</td>
<td>47.7%</td>
</tr>
<tr>
<td>Age (in years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-34</td>
<td>48</td>
<td>44.8%</td>
</tr>
<tr>
<td>35-44</td>
<td>40</td>
<td>37.3%</td>
</tr>
<tr>
<td>≥45</td>
<td>19</td>
<td>17.7%</td>
</tr>
<tr>
<td>Marital status</td>
<td>107</td>
<td>100%</td>
</tr>
<tr>
<td>Married</td>
<td>2</td>
<td>1.8%</td>
</tr>
<tr>
<td>Divorced or Widowed</td>
<td>76</td>
<td>70.9%</td>
</tr>
<tr>
<td>Single</td>
<td>29</td>
<td>27.1%</td>
</tr>
<tr>
<td>Parity</td>
<td>105</td>
<td>100%</td>
</tr>
<tr>
<td>0 child</td>
<td>9</td>
<td>8.5%</td>
</tr>
<tr>
<td>1-3 children</td>
<td>64</td>
<td>60.9%</td>
</tr>
<tr>
<td>4-9 children</td>
<td>24</td>
<td>22.8%</td>
</tr>
<tr>
<td>≥5 children</td>
<td>8</td>
<td>7.6%</td>
</tr>
<tr>
<td>Number of clients/14 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>11</td>
<td>10.3%</td>
</tr>
<tr>
<td>1-9</td>
<td>18</td>
<td>26.1%</td>
</tr>
<tr>
<td>10-49</td>
<td>47</td>
<td>43.8%</td>
</tr>
<tr>
<td>≥50</td>
<td>11</td>
<td>10.3%</td>
</tr>
<tr>
<td>Monthly income in USD</td>
<td>103</td>
<td>96.2%</td>
</tr>
<tr>
<td>≤200</td>
<td>36</td>
<td>34.9%</td>
</tr>
<tr>
<td>200-350</td>
<td>41</td>
<td>39.8%</td>
</tr>
<tr>
<td>&gt;350</td>
<td>26</td>
<td>25.2%</td>
</tr>
<tr>
<td>Sexually transmitted infections (STIsa)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N. gonorrhoeae</td>
<td>104</td>
<td>97.2%</td>
</tr>
<tr>
<td>positive</td>
<td>6</td>
<td>5.7%</td>
</tr>
<tr>
<td>C. trachomatis</td>
<td>104</td>
<td>97.2%</td>
</tr>
<tr>
<td>positive</td>
<td>3</td>
<td>2.8%</td>
</tr>
<tr>
<td>Trichomonas vaginalis</td>
<td>104</td>
<td>97.2%</td>
</tr>
<tr>
<td>positive</td>
<td>1</td>
<td>0.9%</td>
</tr>
<tr>
<td>Vaginal Candidiasis</td>
<td>104</td>
<td>97.2%</td>
</tr>
<tr>
<td>positive</td>
<td>8</td>
<td>7.2%</td>
</tr>
</tbody>
</table>
Mean CD4 count increased progressively from baseline to Month9 then reached a plateau, while %tage of CD4 count <500, as well as number of participants decreased over time.

Both %tage of suppressed and undetectable viral loads decreased over time even in those with final visits.
## Results (3)

### Viral suppression vs adherence

<table>
<thead>
<tr>
<th>Adherence levels (self-reported)</th>
<th>Prevalences</th>
<th>PR&lt;sup&gt;a&lt;/sup&gt;</th>
<th>95%CI&lt;sup&gt;b&lt;/sup&gt;</th>
<th>p value</th>
<th>p trend&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Suppressed viral load</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥90% (Pill missed ≤3)</td>
<td>129/155 (83.2%)</td>
<td>1.4</td>
<td>1.0</td>
<td>2.0</td>
<td>0.04</td>
</tr>
<tr>
<td>75-89% (Pill missed = 4-7)</td>
<td>16/19 (84.2%)</td>
<td>1.4</td>
<td>0.9</td>
<td>2.2</td>
<td>0.10</td>
</tr>
<tr>
<td>50-74% (Pill missed 8-15)</td>
<td>9/11 (81.8%)</td>
<td>1.4</td>
<td>0.9</td>
<td>2.2</td>
<td>0.12</td>
</tr>
<tr>
<td>&lt;50% (Pill missed &gt;15)</td>
<td>13/22 (59.1%)</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>(Reference)</td>
</tr>
<tr>
<td><strong>missing&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>5/10 (50.0%)</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td><strong>Undetectable viral load</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥90% (Pill missed ≤3)</td>
<td>114/155 (73.5%)</td>
<td>3.2</td>
<td>1.5</td>
<td>6.8</td>
<td>0.002</td>
</tr>
<tr>
<td>75-89% (Pill missed = 4-7)</td>
<td>14/19 (73.7%)</td>
<td>3.3</td>
<td>1.5</td>
<td>7.0</td>
<td>0.003</td>
</tr>
<tr>
<td>50-74% (Pill missed 8-15)</td>
<td>8/11 (72.7%)</td>
<td>3.3</td>
<td>1.5</td>
<td>7.1</td>
<td>0.003</td>
</tr>
<tr>
<td>&lt;50% (Pill missed &gt;15)</td>
<td>5/22 (22.7%)</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>(Reference)</td>
</tr>
<tr>
<td><strong>missing&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>4/10 (40.0%)</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>PR: Prevalence ratio  
<sup>b</sup>95%CI: 95% Confidence Interval  
<sup>c</sup>p trend: trend in the prevalence ratio  
<sup>d</sup>Missing: No data available for self-reported adherence for these subjects
Summary of drug resistance

Table 1: Pre-ART drug resistance

<table>
<thead>
<tr>
<th>Pre-ART resistance</th>
<th>Prevalence</th>
<th>Mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total prevalence</td>
<td>10.8% (12/111)</td>
<td></td>
</tr>
<tr>
<td>NRTIs</td>
<td>(3.6%)</td>
<td>M41L, M184V, T215TS, M184I</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>(10%)</td>
<td>K103N, Y181C, Y188L, Y181S</td>
</tr>
<tr>
<td>PIs</td>
<td>0.9%</td>
<td>L90M, L33F, K20I and L10V</td>
</tr>
</tbody>
</table>

Table 2: Emerging drug resistance

<table>
<thead>
<tr>
<th>Emerging resistance</th>
<th>Prevalence</th>
<th>Mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total prevalence</td>
<td>16.7% (2/12)</td>
<td></td>
</tr>
<tr>
<td>NRTIs</td>
<td>20%</td>
<td>M41L, M184V, T215TS, M184I</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>20%</td>
<td>K103N, Y181C, Y188L, Y181S</td>
</tr>
<tr>
<td>PIs</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Note:
- All samples included at baseline were tested for drug resistance
- Most of patients with pre-ART resistance did not show clinical resistance during follow up, showed increased CD4 count, and viral suppression
- At the end of the follow up, 12 samples showed viral load ≥1000 copies/ml, only 2 exhibited mutations associated with resistance to NNRTI or NRTI
First study on **TasP/PrEP** in the West and Central Africa region

- TasP was accepted by the majority of HIV-infected FSWs (96.4%)

- Feasibility was highly affected by mobility (about 40.2% dropped out between recruitment and the end of the study)

- FSWs could also face individual, social, or structural barriers, including anxiety, stigmatization, lack of social support, violence, or discrimination from medical staff, which could prevent them from being fully adherent

- Despite mobility and other barriers, 73.5%-83.2% of participants achieved adherence levels above ≥90%

- Viral load<1000 (<40) was attained in 73.1% (64.6%) of participants at month-6; 84.8% (71.2%) at month-12, and; 80.9% (65.1%) at final visit, respectively.

- TasP coupled with good adherence resulted in CD4 count restoration, increased viral suppression, and low emergence of drug resistance
Conclusion

– Immediate HIV treatment initiation following diagnosis is widely accepted and should be implemented in this region

– Mobility and adherence should be seriously addressed in future interventions programs

– Regional collaboration between FSW-friendly clinics is needed for sustained treatment implementation.

– We fell short of the UNAIDS objective of 90% viral suppression among those treated

– Need for better programs for enhancing treatment adherence, including structural interventions for reducing stigma and discrimination towards female sex workers and HIV-infected individuals
Acknowledgement

Special thanks to
− Dr **Michel Alary** and his team at Hôpital du Saint-Sacrement,
− The CHU de Québec-Université Laval
− The statistician of the SP-POS
− The team of the IST-clinic in Cotonou, Benin
Thank you for your attention

Welcome Questions
## Summary of Pre-ART Drug resistance

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>CD4 count (cell/µl)</th>
<th>Viral load (copies/ml)</th>
<th>Mutations</th>
<th>Resistance levels</th>
<th>ART regimen</th>
<th>HIV Subtypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD009</td>
<td>321</td>
<td>11220</td>
<td>M41L, D67N, T69D, 70R, K103N, V179E</td>
<td>Intermediate to High</td>
<td>3TC, ABC, AZT, D4T, DDI, FTC, TDF, EFV, NVP, ETR, RPV</td>
<td>G/CRF02_AG</td>
</tr>
<tr>
<td>CD011</td>
<td>700</td>
<td>6309</td>
<td>K103N, Y181C</td>
<td>Intermediate to High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD068</td>
<td>305</td>
<td>2800</td>
<td>T215TS, Y181YF, G190A</td>
<td>Low to High</td>
<td>NA</td>
<td>CRF02_AG</td>
</tr>
<tr>
<td>CD083</td>
<td>506</td>
<td>2786</td>
<td>A98G V179E Y188L</td>
<td>Low</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD140</td>
<td>395</td>
<td>10000</td>
<td>Y181YF</td>
<td>Intermediate to High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD191</td>
<td>90</td>
<td>36000</td>
<td>Y181YF</td>
<td>Low to High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD244</td>
<td>720</td>
<td>1900</td>
<td>K103N, P225H</td>
<td>High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD330</td>
<td>78</td>
<td>100968</td>
<td>Y181S</td>
<td>Low to High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>D333</td>
<td>686</td>
<td>3466</td>
<td>M184I</td>
<td>Low to high</td>
<td>NA</td>
<td>CRF11-cpx/CRF02_AG</td>
</tr>
<tr>
<td>CD343</td>
<td>448</td>
<td>2044</td>
<td>K103N</td>
<td>High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD371</td>
<td>1365</td>
<td>1000</td>
<td>Y181YF</td>
<td>Low to High</td>
<td>NA</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
<tr>
<td>CD314</td>
<td>590</td>
<td>12657</td>
<td>L90M, K20I, L21F</td>
<td>High</td>
<td>ABC, AZT, D4T, DDI, FTC, TDF, EFV, NVP, ETR, RPV</td>
<td>CRF02_AG/CRF02_AG</td>
</tr>
</tbody>
</table>

**NRTI**: Nucleoside Reverse Transcriptase Inhibitors; **NNRTI**: Non-Nucleoside Reverse Transcriptase Inhibitors; **PIs**: Protease Inhibitors;

**Class of drugs NRTIs**: Lamivudine (3TC), Abacavir (ABC), Emtricitabine (FTC), zidovudine (AZT), stavudine (D4T), didanosine (DDI), tenofovir (TDF).

**NNRTIs**: efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV), etravirine (ETR).

**PIs**: atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), indinavir/ritonavir (IDV/r), saquinavir/ritonavir (SQV/r), fosamprenavir/ritonavir (FPV/r), nelfinavir (NFV).

**HIV Subtypes**: CRF02_AG/CRF02_AG, G/CRF02_AG and CRF11-cpx/CRF02_AG.
Systemic Sclerosis (SSc) with Interstitial Lung Disease (SSc-ILD) in Canada’s Largest Province: An Estimate of the Prevalence and Survival of SSc and SSc-ILD in Ontario

Presenter: Kobina Quansah, Boehringer-Ingelheim (Canada) Limited

Co-authors: Dr. Janet E. Pope, Dr. Martin Kolb, Jason Flavin and Dr. Kris Garlick
DISCLOSURES

I am an employee of Boehringer-Ingelheim (Canada) Limited
BACKGROUND

- Systemic sclerosis is a rare, chronic and complex autoimmune disease, characterised by extensive vascular injury and progressive fibrosis (scarring) of the skin thickening and internal organ damage.\(^1\)

- When fibrosis occurs in the lungs, it is generally known as Interstitial Lung Disease (ILD) a frequent complication of SSc (SSc-ILD). The ILD usually leads to dyspnea (shortness of breath) caused by stiffening of the lungs.

- After diagnosis with SSc-ILD, some patients may experience a rapid pulmonary decline in the first 3 years of disease.\(^2\)

- SSc-ILD is generally associated with increased morbidity and mortality.\(^3\) The median survival of patients with SSc-ILD is as low as 5 years.\(^2\)

- To date, no published study has generated population based estimates of the prevalence and survival of SSc-ILD in Canada.

OBJECTIVES

• Estimate the prevalence of SSc and SSc-ILD in Ontario
• Describe the demographic profile of SSc and SSc-ILD in Ontario
• Estimate the survival of SSc and SSc-ILD patients in Ontario
STUDY DESIGN AND POPULATION

Retrospective Cohort study using administrative data
- Inpatient hospitalization and day surgery data [Discharge Abstract Database (DAD)]
- Ambulatory care, emergency department and outpatient hospital clinic data [National Ambulatory Care Reporting System (NACRS)]
- ICD 10 CA codes were used to identify patients

Population-Inclusion Criteria
- Ontario adult residents (≥ 18 years of age)
- Valid health card on the first day of the fiscal year (s) of interest (April 1)
- Date of last contact with the health care system within 7 years prior to the first day of the fiscal year of interest (April 1)
- Eligible for the provincial insurance plan on the first day of the fiscal year (s) of interest (April 1)
- Patient identified with a diagnosis between April 1, 2008 to March 31, 2018
COHORT DEFINITIONS- PREVALENCE

- **Prevalent SSc**: defined using M34 codes to identify Systemic Sclerosis (M34.0, M34.1, M34.2, M34.8 and M34.9)

- **Prevalent SSc-ILD**: Any Systemic Sclerosis (any M34 code from above) *only if followed by an occurrence of any of these codes:*
  - J84.1 Other interstitial pulmonary disease with fibrosis
  - J84.8 Other specified interstitial pulmonary diseases
  - J84.9 Interstitial pulmonary disease; unspecified
  - J99.1 Respiratory disorders in the other diffuse connective tissue disorders
RESULTS- COHORT DEMOGRAPHICS

<table>
<thead>
<tr>
<th>Variable</th>
<th>SSc Patients</th>
<th>SSc-ILD Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>3,111</td>
<td>519</td>
</tr>
<tr>
<td>Mean age at index date (years)</td>
<td>57.4 ± 14.3</td>
<td>57.9 ± 12.2</td>
</tr>
<tr>
<td>Females</td>
<td>84.2%</td>
<td>80.2%</td>
</tr>
</tbody>
</table>

Baseline characteristics of patients between 2008 and 2018
### RESULTS- PREVALENCE FOR SSc

#### Crude estimate of SSc (per 100,000)

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Overall*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Group, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-29</td>
<td>0.55</td>
<td>0.96</td>
<td>1.21</td>
<td>1.66</td>
<td>2.45</td>
<td>2.68</td>
<td>2.87</td>
<td>3.21</td>
<td>3.44</td>
<td>3.59</td>
<td>2.29</td>
</tr>
<tr>
<td>30-50</td>
<td>2.77</td>
<td>4.85</td>
<td>6.44</td>
<td>7.6</td>
<td>8.75</td>
<td>9.69</td>
<td>11.05</td>
<td>12.46</td>
<td>13.25</td>
<td>14.1</td>
<td>9.04</td>
</tr>
<tr>
<td>51-64</td>
<td>8.11</td>
<td>13.02</td>
<td>16.84</td>
<td>19.19</td>
<td>21.23</td>
<td>22.75</td>
<td>24.54</td>
<td>26.11</td>
<td>27.14</td>
<td>28.79</td>
<td>21.21</td>
</tr>
<tr>
<td>65+</td>
<td>11.15</td>
<td>17.27</td>
<td>21.18</td>
<td>22.76</td>
<td>25.53</td>
<td>27.57</td>
<td>28.59</td>
<td>29.66</td>
<td>29.54</td>
<td>29.4</td>
<td>24.79</td>
</tr>
<tr>
<td>Sex n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8.09</td>
<td>13.51</td>
<td>17.43</td>
<td>19.94</td>
<td>22.54</td>
<td>24.77</td>
<td>27</td>
<td>29.01</td>
<td>30.06</td>
<td>31.19</td>
<td>22.61</td>
</tr>
<tr>
<td>Male</td>
<td>1.77</td>
<td>2.56</td>
<td>3.21</td>
<td>3.57</td>
<td>4.33</td>
<td>4.6</td>
<td>4.94</td>
<td>5.52</td>
<td>5.81</td>
<td>6.24</td>
<td>4.31</td>
</tr>
</tbody>
</table>

* Overall represents the average prevalence over the 10 year period
## RESULTS - PREVALENCE FOR SSc-ILD

Crude estimate of SSc-ILD (per 100,000)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>1.19</td>
<td>1.77</td>
<td>2.23</td>
<td>2.54</td>
<td>2.69</td>
<td>2.71</td>
<td>2.69</td>
<td>2.73</td>
<td>2.56</td>
<td>2.32</td>
<td>2.36</td>
</tr>
<tr>
<td><strong>Age Group, n(%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-29</td>
<td>*0.05 - 0.27</td>
<td>*0.05 - 0.26</td>
<td>*0.05 - 0.26</td>
<td>*0.05 - 0.26</td>
<td>*0.05 - 0.25</td>
<td>*0.05 - 0.25</td>
<td>*0.05 - 0.25</td>
<td>0</td>
<td>0</td>
<td>*0.05 - 0.26</td>
<td></td>
</tr>
<tr>
<td>30-50</td>
<td>*0.44 - 0.53</td>
<td>*1.02 - 1.12</td>
<td>*1.37 - 1.47</td>
<td>*1.52 - 1.62</td>
<td>*1.53 - 1.63</td>
<td>*1.52 - 1.61</td>
<td>*1.65 - 1.75</td>
<td>1.79 - 1.90</td>
<td>1.88</td>
<td>1.65</td>
<td>1.48</td>
</tr>
<tr>
<td>51-64</td>
<td>2.48</td>
<td>3.35</td>
<td>4.21</td>
<td>4.56</td>
<td>4.74</td>
<td>4.75</td>
<td>4.83</td>
<td>4.61</td>
<td>4.44</td>
<td>4.22</td>
<td>4.26</td>
</tr>
<tr>
<td>65+</td>
<td>2.31</td>
<td>3.04</td>
<td>3.61</td>
<td>4.42</td>
<td>4.9</td>
<td>4.9</td>
<td>4.29</td>
<td>4.38</td>
<td>3.75</td>
<td>3.21</td>
<td>*3.78 - 3.97</td>
</tr>
<tr>
<td><strong>Sex n(%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.85</td>
<td>2.83</td>
<td>3.49</td>
<td>3.97</td>
<td>4.1</td>
<td>4.27</td>
<td>4.29</td>
<td>4.3</td>
<td>3.97</td>
<td>3.61</td>
<td>3.69</td>
</tr>
<tr>
<td>Male</td>
<td>0.5</td>
<td>0.66</td>
<td>0.89</td>
<td>1.02</td>
<td>1.2</td>
<td>1.07</td>
<td>1</td>
<td>1.07</td>
<td>1.07</td>
<td>0.95</td>
<td>0.95</td>
</tr>
</tbody>
</table>

* Exact counts suppressed for privacy reasons
°Overall represents the average prevalence over the 10 year period
Results - SSc Survival

The survival rates at one, five and ten years after diagnosis were 85.0%, 64.5% and 44.9%, respectively.

[Graph showing survival probability over time]
The survival rates at one, five and ten years after diagnosis were 77.1%, 44.4% and 22.0%, respectively.
CONCLUSIONS

• SSc prevalence rates found in this study are in line with findings from a recent systematic review of published literature based on North American results (13.5 – 44.3 per 100,000 persons).³

• Survival rates for SSc at 1, 5 and 10 years are similar to findings from a comprehensive SR and MA of the published literature.⁴

• SSc-ILD prevalence and survival rates could not be compared with the literature due to lack of published results.

• This study suggest a lower survival rate for SSc-ILD than for SSc. The 5-year survival for SSc-ILD is similar to that of multiple myeloma.⁵

• Results confirm that the prevalence of SSc-ILD may fall within a Canadian threshold for drugs for ‘other’ rare disease.⁶

Source:
FUTURE INVESTIGATIONS

• Potential “second look” can include looking at a community-definition using physician and diagnostic procedure codes to capture a population diagnosed outside of the hospital
ACKNOWLEDGEMENTS

• Drs. Martin Kolb and Janet E Pope provided input on the study design, interpretation findings, definition of indications and the abstract

• Jason Flavin and Kris Garlick provided input into the study design, interpretation of findings and drafting of the abstract

• Shazia Hassan and Soo Jin Seung provided input into the study design, interpretation and presentation of findings

• This study made use of de-identified data from the ICES Data Repository, which is managed by the Institute for Clinical Evaluative Sciences with support from its funders and partners: Canada's Strategy for Patient-Oriented Research (SPOR), the Ontario SPOR Support Unit, the Canadian Institutes of Health Research and the Government of Ontario. The opinions, results and conclusions reported are those of the authors. No endorsement by ICES or any of its funders or partners is intended or should be inferred.
QUESTIONS?